LU92976I2 - Asfotase alfa - Google Patents

Asfotase alfa Download PDF

Info

Publication number
LU92976I2
LU92976I2 LU92976C LU92976C LU92976I2 LU 92976 I2 LU92976 I2 LU 92976I2 LU 92976 C LU92976 C LU 92976C LU 92976 C LU92976 C LU 92976C LU 92976 I2 LU92976 I2 LU 92976I2
Authority
LU
Luxembourg
Prior art keywords
amino acid
absent
acid sequence
asfotase alfa
salp
Prior art date
Application number
LU92976C
Other languages
English (en)
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of LU92976I2 publication Critical patent/LU92976I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
LU92976C 2007-05-11 2016-02-10 Asfotase alfa LU92976I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
PCT/CA2008/000923 WO2008138131A1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Publications (1)

Publication Number Publication Date
LU92976I2 true LU92976I2 (en) 2016-04-11

Family

ID=40001639

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92976C LU92976I2 (en) 2007-05-11 2016-02-10 Asfotase alfa

Country Status (25)

Country Link
US (1) US20100297119A1 (xx)
EP (3) EP2662448B1 (xx)
JP (1) JP5732603B2 (xx)
AT (1) ATE536413T1 (xx)
AU (1) AU2008250945B2 (xx)
BR (2) BR122019000505B1 (xx)
CA (1) CA2687001C (xx)
CY (1) CY2016005I2 (xx)
DE (1) DE202008018131U1 (xx)
DK (3) DK2368999T3 (xx)
ES (3) ES2471915T3 (xx)
FR (1) FR16C0007I2 (xx)
HR (1) HRP20140416T1 (xx)
HU (2) HUE031655T2 (xx)
IL (1) IL202057A0 (xx)
LT (1) LTC2368999I2 (xx)
LU (1) LU92976I2 (xx)
ME (1) ME01828B (xx)
NL (1) NL300798I1 (xx)
NO (1) NO2016002I2 (xx)
PL (3) PL2662448T3 (xx)
PT (3) PT2158319E (xx)
RS (1) RS53302B (xx)
SI (2) SI2368999T1 (xx)
WO (1) WO2008138131A1 (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
CN103897063B (zh) 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
EP2545080B1 (en) 2010-03-12 2017-05-10 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
EP2563406A4 (en) * 2010-04-30 2013-11-13 Alexion Pharma Internat Sarl METHOD, COMPOSITIONS AND KITS FOR TREATING MATRIX MINERALIZATION DISORDERS
EP3543257A1 (en) 2010-07-28 2019-09-25 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
EP3425048A1 (en) * 2014-01-24 2019-01-09 AM-Pharma B.V. Chimeric alkaline phosphatase-like proteins
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
WO2016090251A1 (en) * 2014-12-05 2016-06-09 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
AU2016308624B2 (en) * 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) * 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
EP3426286A4 (en) * 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
WO2017173395A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20180125979A (ko) * 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
US20200306350A1 (en) 2016-06-27 2020-10-01 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
BR112019011070A2 (pt) * 2016-11-30 2019-10-01 Purdue Research Foundation regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoide
EP3551647A4 (en) 2016-12-09 2021-01-13 Gliknik Inc. MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
EP3592372A4 (en) * 2017-03-09 2021-01-13 Alexion Pharmaceuticals, Inc. GLYCOPROTEIN MANUFACTURING PROCESS
MX2019011508A (es) 2017-03-31 2019-11-01 Alexion Pharma Inc Metodos para tratar la hipofosfatasia (hpp) en adultos y adolescentes.
JP7511469B2 (ja) 2017-09-27 2024-07-05 イノザイム ファーマ， インコーポレイテッド 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
EP3790574A4 (en) 2018-05-30 2022-07-13 Purdue Research Foundation TARGETING ANABOLIC DRUGS TO ACCELERATE FRACTURE REPAIR
JP7820148B2 (ja) 2018-08-10 2026-02-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
KR20220005560A (ko) 2019-05-06 2022-01-13 신세틱 바이오로직스, 인코퍼레이티드 알칼리성 포스페이트-기반 종양학 치료제
MX2022007114A (es) * 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.
EP4084819A1 (en) 2020-01-03 2022-11-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Tnap locally administered for promoting periodontal health
CN116848146A (zh) * 2020-09-03 2023-10-03 I·S·Y·陈 可溶性碱性磷酸酶构建体和包含编码可溶性碱性磷酸酶构建体的多核苷酸的表达载体
MX2023002673A (es) 2020-09-04 2023-05-12 Alexion Pharma Inc Métodos para el tratamiento de trastornos de mineralización ósea.
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
EP4291224A4 (en) 2021-02-12 2025-01-01 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
EP4581048A2 (en) * 2022-08-31 2025-07-09 University of Utah Research Foundation Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE60034478T2 (de) 1999-11-16 2008-01-10 Genzyme Corp., Cambridge Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
EP1395293B1 (en) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
EP1781318A4 (en) 2004-06-23 2009-12-23 Genzyme Corp METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYKYSTIC DISEASES
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
CN101068575A (zh) 2004-12-01 2007-11-07 建新公司 向肝脏定向递送遗传物质的方法

Also Published As

Publication number Publication date
JP5732603B2 (ja) 2015-06-10
NO2016002I1 (no) 2016-02-02
AU2008250945A1 (en) 2008-11-20
FR16C0007I2 (fr) 2017-01-27
CY2016005I1 (el) 2016-08-31
BRPI0811198B8 (pt) 2021-05-25
LTC2368999I2 (lt) 2017-09-25
CA2687001C (en) 2019-02-12
ES2380546T3 (es) 2012-05-16
HRP20140416T1 (hr) 2014-06-20
CY2016005I2 (el) 2016-08-31
EP2368999A1 (en) 2011-09-28
DK2368999T3 (da) 2014-05-26
NO2016002I2 (no) 2016-02-02
HK1141047A1 (en) 2010-10-29
FR16C0007I1 (xx) 2016-04-15
ES2471915T3 (es) 2014-06-27
LTPA2016004I1 (lt) 2016-02-25
RS53302B (sr) 2014-08-29
EP2158319A1 (en) 2010-03-03
WO2008138131A1 (en) 2008-11-20
NL300798I2 (xx) 2016-03-16
HK1162589A1 (en) 2012-08-31
PT2662448T (pt) 2017-03-29
ATE536413T1 (de) 2011-12-15
PL2662448T3 (pl) 2017-07-31
US20100297119A1 (en) 2010-11-25
BRPI0811198A8 (pt) 2018-08-14
BR122019000505A2 (pt) 2021-12-14
DK2662448T3 (en) 2017-03-20
ES2619332T3 (es) 2017-06-26
PL2368999T3 (pl) 2014-08-29
AU2008250945B2 (en) 2013-12-12
AU2008250945A2 (en) 2009-12-24
HK1191372A1 (en) 2014-07-25
HUS1600005I1 (hu) 2016-02-29
CA2687001A1 (en) 2008-11-20
PT2368999E (pt) 2014-05-26
WO2008138131A4 (en) 2008-12-31
EP2662448B1 (en) 2016-12-21
EP2158319A4 (en) 2010-07-21
IL202057A0 (en) 2011-08-01
ME01828B (me) 2014-12-20
WO2008138131A9 (en) 2009-08-06
DE202008018131U1 (de) 2011-12-30
NL300798I1 (xx) 2016-03-16
PL2158319T4 (pl) 2016-04-29
PL2158319T3 (pl) 2012-05-31
BRPI0811198A2 (pt) 2014-10-21
EP2368999B1 (en) 2014-03-12
DK2158319T3 (da) 2012-03-19
JP2010526543A (ja) 2010-08-05
EP2158319B1 (en) 2011-12-07
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
BRPI0811198B1 (pt) 2021-03-09
SI2368999T1 (sl) 2014-07-31
BR122019000505B1 (pt) 2022-01-18
PT2158319E (pt) 2012-03-06
SI2662448T1 (sl) 2017-05-31

Similar Documents

Publication Publication Date Title
NL300798I1 (xx)
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
IL186741A0 (en) Optical probe for delivery of light
ATE481987T1 (de) Verfahren zur radiofluoridierung von biologisch aktiven vektoren
UA103215C2 (uk) Поліпептид з ксиланазною активністю
MY151985A (en) Dental wipe
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
BRPI0414598A (pt) indóis substituìdos
BR0110999A (pt) Misturas de adesivos aquosos
TW200630367A (en) Substituted adenines and the uses thereof
DE602007010969D1 (de) Zytokinderivate
SE0302103D0 (sv) Xylanases with enhanced thermophilicity and alkalophilicity
DK2084198T3 (da) Beklædningssammensætning
ES2573462T3 (es) Polipéptidos de PH20 soluble extendida y usos de los mismos
PT1370513E (pt) Sais de adicao do acido malico de terbinafina
TW200613604A (en) Preparation of fabrics having lotus leaf effect and fabrics having lotus leaf effect
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
ATE539762T1 (de) Aminosäureersatz für peptidkonstruktionen
ATE458507T1 (de) Implantat mit mehrfachbeschichtung
MY150639A (en) T cell adhesion molecule and antibody thereto
CY1115263T1 (el) Αλκαλικη φωσφαταση στοχευμενη στα οστα, κιτ και μεθοδοι χρησης αυτων
UA87361C2 (ru) КАЛИЙ N-(9-ФЛУОРЕНИЛИДЕН)-N'-м-АНИСОГИДРАЗОНАТ, КОТОРЫЙ ПРОЯВЛЯЕТ ПРОТИВОТУБЕРКУЛЕЗНОЕ ДЕЙСТВИЕ
TW200716666A (en) Isolated photoprotein gr-bolinopsin, and its use